Positive outcome for Aerocrine in patent proceedings against Medisoft in Belgium

SOLNA, Sweden - 29 June, 2012 - Aerocrine AB (OMX Nordic Exchange: AERO) today
announced the positive outcome of its complaint against Medisoft S.A. filed at
the Liège Commercial Court, Belgium.
On 14 October 2011, Aerocrine started infringement proceedings against the
Belgian company Medisoft S.A. before the Liège Commercial Court, on the basis of
four of Aerocrine´s patents. Medisoft challenged both infringement and the
validity of the patents as part of its defense. The oral hearings on the merits
took place during the spring 2012.

Yesterday the Court upheld Aerocrine’s patents EP 1,439,781 and EP 1,661,514 as
valid and ruled that both the Medisoft Hyp’Air FeNO and Hyp’Air FeNO+ devices
infringe these patents. Accordingly, Medisoft which is headquartered in Belgium,
will be immediately prohibited as from service of the decision, from
manufacturing, using, maintaining, detaining and offering for sale any Hyp’Air
products.

The Court also invalidated Aerocrine´s earliest patents EP 0,606,351 and EP
0,724,723 for Belgium. These patents expire in 2012 and 2014.

The judgment may be appealed by both parties.

For more information, contact:

Scott Myers, CEO, Aerocrine AB, +46 768 788 379

Mats Carlson, Chief Technology Officer, Aerocrine, AB +46 8 629 07 83
About Aerocrine

Aerocrine AB is a medical technology company focused on the improved management
and care of patients with inflammatory airway diseases. As the pioneer and
leader in the technology to monitor and manage airway inflammation, Aerocrine
markets NIOX® Flex and NIOX MINO®. Both products enable fast and reliable
management of airway inflammation and may therefore play a critical role in more
effective diagnosis, treatment and follow-up of patients with inflammatory
airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries
in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm
Stock Exchange on 15 June 2007. Aerocrine discloses the information provided
herein pursuant to the Securities Markets Act and/or the Financial Instruments
Trading Act. The information was submitted for publication at 08:00 a.m.
on June 29, 2012.